Blood Platelets and Myocardial Infarction: Do Hyperactive Platelets Really Exist?*

Rüdiger E. Scharf  Rainer B. Zotz
Institut für Hämostaseologie und Transfusionsmedizin, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany

Key Words
Myocardial infarction · Platelet receptor polymorphisms · Platelet thrombogenicity · Human platelet antigens (HPA) · Arterial thrombogenesis

Summary
The existence of platelet ‘hyperreactivity’ as a trigger of acute vascular events has been postulated clinically for decades. However, the molecular nature of an intrinsically enhanced platelet function remained unknown. Recently, a possible explanation was provided in that several genetically determined variants of platelet glycoprotein receptors can be responsible for an increased thrombogenicity and thereby accelerate acute occlusive complications of arterial disease. Distinct polymorphisms within the genes of platelet membrane glycoprotein receptors can alter their antigenicity, regulate, at least in part, their expression levels on the platelet surface, and modify their functional properties with regard to ligand binding and adhesion activity. This review will focus on 2 essential platelet receptors, the integrins αIIbβ3 and α2β1, their polymorphisms, and their potential clinical impact of genetically determined receptor variants on cardiovascular disease. Moreover, the genotype-to-phenotype relation of relevant platelet receptor variants will be discussed, and an attempt is made to assess the interdependency of phenotype to disease.

Schlüsselwörter
Myokardinfarkt · Plättchen-Rezeptor-Polymorphismen · Plättchenthrombogenität · Humane Plättchenantigene (HPA) · Arterielle Thrombogenese

Zusammenfassung

* Dedicated to Prof. Dr. Peter Hanfland, Bonn, on the occasion of his 65th birthday.
Introduction

Blood platelets play a pivotal role in hemostasis and arterial thrombogenesis. They are anuclear fragments derived from the cytoplasm of megakaryocytes. Upon release from the bone marrow into the circulation, platelets contribute essentially to survey the integrity of the vascular system. Specifically, they respond immediately to vascular lesions by becoming adherent within milliseconds and by forming aggregates at sites of injured endothelial cells or exposed subendothelial matrix structures. Following activation, platelets provide a highly effective catalytic membrane surface for the generation of thrombin which, in turn, accelerates recruitment of circulating resting platelets and, particularly, formation of fibrin necessary to stabilize thrombi and to prevent their detachment by flowing blood. Once stimulated, platelets respond uniformly and do not distinguish between traumatic injury and pathological (e.g. atherosclerotic) damage of the vessel wall. While their physiological function is to support arrest of bleeding, to contribute to wound healing and to restore vessel wall integrity, platelets can form occlusive thrombi as a consequence of vascular diseases, such as atherosclerosis. Thus, under pathological conditions, platelet responses can result in acute ischemic syndromes of the heart, brain and other organ systems. This review will address the nature of increased platelet thrombogenicity with emphasis on the role of distinct platelet membrane receptor polymorphisms. Moreover, the genotype-to-phenotype and the phenotype-to-disease relations of specific platelet integrin variants will be discussed in further detail.

The Prethrombotic State and Platelet Hyperaggregability

Numerous experimental and clinical studies have documented that acute vascular events cause platelet activation and formation of platelet thrombi which, in turn, can lead to unstable angina, myocardial infarction or stroke [1–3]. For example, platelet activation occurs at the site of a fissured coronary atherosclerotic plaque with exposure of highly thrombogenic substances. We have examined the effect of angioplasty-injured coronary arteries on platelet activation [4]. Using flow cytometric techniques in combination with specific conformation-dependent monoclonal antibodies (mAbs), activated platelets could be demonstrated in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) (fig. 1). By contrast to these conditions in which platelet activation and thrombus formation emerge in response to the exposure of subendothelial extracellular matrix proteins, less well documented and perhaps less frequently, are several clinical settings in which an acute vascular event appears to result from an intrinsic platelet activation.

We studied 47 patients (12 males, 35 females, <45 years of age) with cerebral ischemia (stroke) of unknown cause and 36 patients (6 males, 30 females, mean age 38 years) suffering from migraine accompagnée [2]. Elevated plasma concentrations of platelet-specific proteins, including β-thromboglobulin (βTG) and platelet factor 4 (PF4), were found in 33 of the 47 patients with stroke (70%) and in 25 of the 36 patients with migraine accompagnée (69%). Interestingly, the plasma levels of βTG and PF4 correlated inversely (r = –0.72, p < 0.001) with the interval between time of the migraine attack and blood collection (fig. 2), suggesting a direct association of increased platelet secretion with clinical symptoms [2]. This observation is in accordance with findings from others who reported on an augmented rate of circulating platelet aggregates in patients with migraine accompagnée, in particular at the time of a migraine attack [5].

Along with suchlike findings, it has been postulated clinically that hyperreactive or hyperreactive platelets exist in affected individuals [6, 7]. From a laboratory point of view, this condition has been termed platelet hyperaggregability, defined as a feature in which the threshold concentration for aggregating agents, including adenosine diphosphate (ADP), epinephrine and collagen, is lowered in patients [6, 8] and, as very recently demonstrated, also in healthy individuals [7]. This phenomenon has to be carefully distinguished from the so-called ‘sticky platelet syndrome’, an autosomal dominant platelet disorder characterized by hyperaggregability of platelets in response to ADP and epinephrine (type I), epinephrine alone (type II) or ADP alone (type III) and associated with arterial and/or venous thrombembolic events [9]. In a more general way, the term ‘prethrombotic state’ has been introduced. This state is postulated to represent a condition which precedes clinically overt thrombosis, during which the hemostatic function is altered in a way that promotes formation or deposition of platelet thrombi and generation of fibrin [6]. This definition raises several questions: i) What are the markers of such a prethrombotic state and ii) what is its molecular nature? In this context, polymorphisms of platelet membrane glycoproteins have come into the focus of interest.

Polymorphisms of Platelet Membrane Glycoproteins

Polymorphisms are stable DNA sequence variations that occur in more than 1% of chromosomes in the general population. Platelet membrane glycoproteins are highly polymorphic and can be recognized as self-antigens or alloantigens. Incompatibility of distinct epitopes, also known as human platelet antigens, on the various platelet membrane receptors is responsible for alloimmune thrombocytopenia and some cases of platelet transfusion refractoriness. Moreover, ‘mismatches’ play an important role in the pathogenesis of fetal or neonatal alloimmune thrombocytopenia and posttransfusion purpura. Among platelet membrane glycoproteins, a variety of adhesion receptors of the integrin and nonintegrin family has been identified. Most receptors carry distinct polymorphisms which are summarized in table 1.
Hyperactive Platelets and Myocardial Infarction

Normal platelets contain approximately 80,000 receptor copies of integrin αIIbβ3, also known as GPIIb-IIIa, 80% of which are randomly distributed and expressed on the platelet surface in its resting state, making this perhaps the most abundant receptor for adhesion and aggregation of any cell [10]. The remaining but substantial population of αIIbβ3 is located within the surface-connected canalicular system and within the membranes of α-granules. These ‘internal’ pools of αIIbβ3 become surface-expressed and function-capable upon platelet activation [10]. αIIbβ3 can interact with fibrinogen, von Willebrand factor, fibronectin, vitronectin or thrombospondin and is the principal receptor for platelet aggregation. αIIbβ3 carries the human platelet antigen 1 (HPA-1) and other well-defined diallelic alloantigen systems [11]. The HPA-1 polymorphism arises from a single T→C nucleotide substitution at position 1565 in exon 2 of the β3 gene, which, in turn, leads to an amino acid change at position 33 in the β3 subunit (GPIIIa) with leucine in HPA-1a (P1A1) and proline in HPA-1b (P1A2) [12]. Importantly, the HPA-1b allele is not rare; approximately 25% of Europeans have at least 1 allele [11].
Table 1. Polymorphisms of platelet membrane glycoproteins. Human platelet antigens (HPA)

<table>
<thead>
<tr>
<th>New nomenclature</th>
<th>Antigen (other names)</th>
<th>GP (integrin subunit)</th>
<th>Aminoacid dimorphism</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPA-1a</td>
<td>PlA1 (Zw+)</td>
<td>GPIIIa (β3)</td>
<td>Leu 33 → Pro</td>
</tr>
<tr>
<td>HPA-1b</td>
<td>PlA2 (Zw+)</td>
<td>GPIIbα*</td>
<td>Thr 145 → Met</td>
</tr>
<tr>
<td>HPA-2a</td>
<td>Koβ</td>
<td>GPIIb           (αIIb)</td>
<td>Ile 843 → Ser</td>
</tr>
<tr>
<td>HPA-3a</td>
<td>Bak* (Lek*)</td>
<td>GPIIIa (β3)</td>
<td>Gln 143 → Arg</td>
</tr>
<tr>
<td>HPA-3b</td>
<td>Bakβ</td>
<td>GPIIb           (αIIb)</td>
<td></td>
</tr>
<tr>
<td>HPA-4a</td>
<td>Pen* (Yuk*)</td>
<td>GPIIIa (β3)</td>
<td></td>
</tr>
<tr>
<td>HPA-4b</td>
<td>Penβ (Yukβ)</td>
<td>GPIIa (α2)**</td>
<td>Glu 505 → Lys</td>
</tr>
<tr>
<td>HPA-5a</td>
<td>Brb (Zb*)</td>
<td>GPIa (α2)**</td>
<td></td>
</tr>
<tr>
<td>HPA-5b</td>
<td>Br* (Zy*)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GP = Glycoprotein.
*The GPIIb-IX-V receptor complex is a non-integrin.
** At least 3 alleles of the α2 gene are defined by 8 nucleotide polymorphisms (807C/T; 837 T/C; 873G/A; 1648G/A). The 1648G/A polymorphism is responsible for HPA-5.

Polymorphisms of α2β1 (GPIa-IIa): α2 C807T and HPA-5 (Br)

Platelets contain several receptors for collagen, including GPVI and integrin α2β1, also known as GPIa-IIa, both of which are important for platelet adhesion. It is now recognized that platelet adhesion to collagen requires prior activation of integrins through ‘inside-out’ signals generated by GPVI and reinforced by released second-wave mediators, such as ADP and thromboxane A2 [13, 14]. α2β1 exhibits at least 3 alleles of the α2 gene which are defined by 8 nucleotide polymorphisms (807C/T; 837 T/C; 873G/A; 1648G/A) [15, 16]. The polymorphisms at positions 807 and 873 are silent, not altering an amino acid, while the 1648G/A polymorphism causes an amino acid substitution (Glu → Lys) at residue 505 responsible for HPA-5 with Glu in HPA-5a (Brb) and Lys in HPA-5b (Brb). What has been of great interest, is the finding that, though the receptor is expressed at low density on the platelet surface (1,000–3,000 receptor copies per platelet), there is a wide, approximately 10-fold, variation among normal individuals that can modulate platelet responses to collagen [15, 16]. Allele 1 (807T/837T/873A/1648G), also referred to as α2 807T, is associated with increased surface expression of α2β1 (high-density variant), while alleles 2 (807C/837T/873G/1648G) and 3 (807C/837C/873G/1648A), also designated α2 807C, are associated with low surface expression of the receptor [16]. Indeed, the rate of platelet attachment to type I collagen in whole blood under conditions of high shear (1,500 s⁻¹) is proportional to the density of α2β1 receptor copies on the platelet surface [16]. The frequency of allele 1 and allele 2 is 39 and 53%, respectively, that of allele 3 is 7% [15].

Clinical Studies: Role of HPA-1b and α2 807TT – Pros and Cons

HPA-1b

In 1996, Weiss et al. [17] first reported on an association between the HPA-1b genotype and the risk of myocardial infarction or unstable angina. The prevalence of HPA-1b in patients admitted to a cardiac care unit was significantly higher than in hospitalized patients without coronary artery disease (CAD) (39.4 vs. 19.1%, odds ratio 2.8, p = 0.01). In patients whose cardiovascular event occurred prior to the age of 60 years, there was an even greater difference between cases and controls (50 vs. 13.9%, odds ratio 6.2, p = 0.002). By contrast, no such difference in the prevalence of HPA-1b was documented when data of the Physician’s Health Study were analyzed prospectively comparing patients who experienced a myocardial infarction with matched controls without cardiovascular events (25.2 vs. 26.4%, p = 0.4) [18]. These two studies may be representative for the discrepant results published in subsequent papers [for review see 19–21]. Since then, the reasons for the conflicting findings have been a matter of ongoing debate. The same is true for the C807T polymorphism of integrin α2β1.
In 1999, Moshfegh et al. [22] found a significant higher prevalence of the α2 807TT genotype in patients with myocardial infarction as compared to healthy controls (16.4 vs. 2.6%, p = 0.022). However, this association appeared highly doubtful since the control group was rather small and the prevalence of 5.6% in the controls differed from the expected prevalence in Caucasians which is about 15% for the α2 807TT genotype [21]. In a large study with 2,237 male patients, no significant association of the α2β3 receptor variant and myocardial infarction was observed [23]. However, in subgroups of younger patients (<62 or <49 years), an increased risk for carriers of the T-allele was shown (odds ratio 1.57, p = 0.004 and 2.61, p = 0.009, respectively). Again, views differ regarding the results of these association studies [21].

Is HPA-1b a Prothrombotic Risk Determinant?

To address this issue, we performed a retrospective study of 298 men, including 124 individuals with myocardial infarction, 83 individuals with CAD but no history of myocardial infarction, and 91 control patients who all had undergone coronary angiography [24]. The overall prevalence of HPA-1b among case patients with myocardial infarction (23%) and control patients (25%) did not differ (p = 0.75). This finding confirmed the Physician’s Health Study [18]. However, a further analysis of our data revealed that the prevalence of HPA-1b was related to the patients’ age and dependent on the time after myocardial infarction with highest values in younger patients (≤60 years) with myocardial infarction and patients with recent onset (<1 year) myocardial infarction (45 vs. 23% in controls, odds ratio 2.0, p = 0.007). Thus, we could document a significant association between the HPA-1b genotype and acute or recent onset myocardial infarction and thereby confirm the observation of Weiss et al. [17]. Moreover, we found that patients with CAD who are carriers of the HPA-1b allele experience a myocardial infarction earlier in life than patients who are HPA-1b-negative [24]. The findings of our study have led to the following preliminary conclusion: The HPA-1b genotype of integrin αIIbβ3 is not a risk factor for atherosclerosis but a risk factor for arterial thrombosis.

Working Hypothesis: HPA-1b is a Risk Factor of Increased Thrombogenicity

Based on this conclusion, we hypothesized that HPA-1b is a prothrombotic risk determinant which requires the presence of an atherosclerotic lesion to become effective. Thus, unlike conventional risk factors, HPA-1b does not represent a risk factor for CAD itself but appears to be associated with increased platelet thrombogenicity. This contention provides an explanation for some of the conflicting results presented in various clinical association studies regarding the role of the HPA-1 polymorphism of integrin αIIbβ3 in patients with CAD. Along with our hypothesis, it can be anticipated that even in prospective studies (e.g., the Physician’s Health Study [18]), the effect of a polymorphism coupled with the presence of CAD will provide no difference in the prevalence of HPA-1b between a patient group with myocardial infarction and a control group, since the genetically determined receptor variant is not associated with an increased rate of myocardial infarction but a premature onset of myocardial infarction. Our hypothesis is illustrated schematically in figure 3. Along with this contention, there are several implications for future investigations: i) Prospective studies with precisely defined clinical endpoints are required. ii) Any selection bias due to recruitment of patients, controls or both and any post-data collection search for significance must be excluded by following strictly predefined criteria. iii) Apart from studies with a case control design, analyses using a case-only design are required. iv) Despite their interaction and interdependency in atherothrombotic disorders, a clear distinction has to be made between risk factors causing arteriosclerosis and those leading to increased thrombogenicity and, thus, accelerating thrombotic occlusion of already diseased arteries.

Prospective Study

We prospectively determined the HPA-1 genotype in 261 consecutive patients prior to saphenous-vein coronary artery by-
pass grafting and performed a follow-up over 1 year [25]. Among patients with bypass occlusion, myocardial infarction or death more than 30 days after surgery, the prevalence of HPA-1b was significantly higher than among patients without postoperative complications (60 vs. 24%, odds ratio 4.7, p < 0.05). Using a stepwise logistic regression analysis with the variables HPA-1b, age, sex, body mass index, smoking, hypertension, diabetes mellitus, cholesterol and triglyceride concentration, only HPA-1b had a significant association with bypass occlusion, myocardial infarctions or death after bypass surgery (odds ratio 4.7, p = 0.019) [25]. These results are compatible with our hypothesis that HPA-1b is a risk factor for increased thrombogenicity. In the opinion of others [26], this study is remarkable for 2 reasons: i) It is the only prospective HPA-1b study to examine the outcome after bypass surgery so far, and ii) the significant association between HPA-1b and poor outcome shows one of highest odds ratios ever reported in any study.

**Premature Myocardial Infarction in Carriers of HPA-1b and α2 807TT with Coronary Artery Disease**

Our hypotheses would be further supported by demonstrating that i) no association between CAD and the prothrombotic receptor variants exists, and that ii) patients with CAD carrying the critical genotypes experience a myocardial infarction earlier in life. To address these items, we genotyped 3,261 extensively characterized and well-documented patients of the prospective Ludwigshafen Risk and Cardiovascular Health (LURIC) project, including 1,175 survivors of a myocardial infarction, 1,211 individuals with CAD but no history of myocardial infarction, 571 control patients without angiographically detectable CAD and, in addition, 793 blood donors [27]. All subgroups and exclusion criteria were specified prior to the initiation of data analysis based on the results of our previous study in another population [24]. In a case-control design, the prevalence of HPA-1b and α2
Platelet Functional Characteristics by HPA-1b Genotype

The results of positive clinical association studies between platelet polymorphisms and CAD require characterization of the phenotypes. What are the functional consequences of integrin receptor variants if there are any?

Fibrinogen Binding

We have used flow cytometry and FITC-conjugated human fibrinogen to study the ligand binding function of integrin αIIbβ3 upon platelet stimulation with increasing concentrations of ADP comparing HPA-1a/1a with HPA-1a/1b and HPA-1b/1b genotypes [28]. At ADP concentrations of 0.5 × 10^{-6} mol/l and 10^{-6} mol/l, specific binding of fibrinogen to HPA-1b-positive platelets was significantly higher than to HPA-1b-negative platelets (p < 0.009 and p < 0.034, respectively). This difference was not related to the receptor density of αIIbβ3 or platelet volume. Our findings were confirmed by Goodall et al. [29] but not by others [30].

Aggregation and Activation Studies

In a large study enrolling 1,422 individuals, a significantly lower epinephrine threshold concentration was required to induce aggregation in HPA-1b-positive platelets [31, 32]. Likewise, when neoantigens and neoepitopes such as P-selectin and LIBS1 were determined, HPA-1b-positive platelets had a higher sensitivity than HPA-1a/1a platelets in response to low-dose ADP or epinephrine [33]. We found a significantly increased surface expression of P-selectin, LIBS1, LAMP3, αIIbβ3-bound fibrinogen and activated αIIbβ3 upon stimulation with low-dose ADP in HPA-1b-positive platelets as compared to the homozygous HPA-1a genotype [34]. Aspirin inhibition also varies by HPA-1 genotype [33]. Thus, HPA-1b-positive platelets are hyperreactive and reveal an altered sensitivity to antiplatelet agents. However, in contrast to the results of Michelson et al. [33], we did not find significant differences between HPA-1a/1a, HPA-1a/1b and HPA-1b/1b platelets of patients with stable CAD (132 men, 45 women, aged 64 ± 0.9 years) or healthy individuals (45 men, 17 women, aged 38 ± 1.5 years) with respect to in vitro inhibition of abciximab, tirofiban or eptifibatide [35].

In summary, functional characterization of HPA-1b-positive platelets argues for a prothrombotic phenotype. However, the findings reported from several laboratories are by no means uniform and consistent. To address this problem in further detail, we have used an established model to study platelet adhesion and thrombus formation under conditions simulating atherosclerotic lesions and arterial flow [36–38].

Modulation of Platelet Adhesion, Aggregation and Thrombus Formation by Integrin Receptor Variants under Arterial Flow Conditions

The experimental design and the principle of the technique and equipment used to study platelet adhesion onto thrombogenic matrices at defined shear rates are depicted in figure 5.
In brief, whole blood from healthy individuals, anticoagulated with either PPACK, a direct thrombin inhibitor, or, depending on the type of experiment, trisodium citrate was incubated with mepacrine to render platelets fluorescent. Blood was aspirated with a syringe pump (Harvard Apparatus Inc., Boston, MA, USA) through a parallel-plate rectangular perfusion chamber (flow path height: 80 μm) at a flow rate of 160 or 480 µl per min to provide wall shear rates of 500 or 1,500 s⁻¹, respectively. Prior to perfusion, glass cover slips were coated with human fibrinogen, fibrillar type I collagen or extracellular matrix secreted and deposited by growing endothelial cells with human fibrinogen, fibrillar type I collagen or extracellular matrix secreted and deposited by growing endothelial cells. Prior to perfusion, glass cover slips were placed in a parallel plate flow chamber that was perfused through the chamber for 5 min at a shear rate of 1,500 s⁻¹. Each single frame image corresponds to an area of 980 × 980 μm. The 3 top panels show adhesion of platelets with the putative prothrombotic genotypes, i.e. HPA-1b/1b of integrin αIIbβ3 or α2 807TT of integrin α2β1, onto immobilized fibrinogen (left frame) or type I collagen (right frame), respectively. The 3 bottom panels show adhesion of platelets with the uncritical ‘wild-type’ receptor form, i.e. HPA-1a/1a or α2 807CC, under identical experimental conditions. The 2 middle panels represent control experiments with HPA-1b/1b platelets. Addition of abciximab, an αIIbβ3 blocking mAb, at a final concentration of 4 µg/ml caused >99% inhibition of platelet adhesion onto fibrinogen. No platelet adhesion was detected when coverslips had been coated with BSA. Note the presence of platelet aggregates (thrombi) on the collagen surface. These images are representative of the results obtained in 60 experiments with blood from healthy donors.

Initial adhesion onto type I collagen

Abciximab (4 µg/ml)

Ratio 5 min / 1 min

Fig. 6. Real-time observation of platelet adhesion onto surface-bound fibrinogen, type I collagen or BSA under flow conditions. Substrates coated onto glass coverslips were placed in a parallel plate flow chamber that produces a variable wall shear rate. Blood containing PPACK as anticoagulant and treated with the fluorescent dye mepacrine for platelet visualization was perfused through the chamber for 5 min at a shear rate of 1,500 s⁻¹. Each single frame image corresponds to an area of 980 × 980 μm. The 3 top panels show adhesion of platelets with the putative prothrombotic genotypes, i.e. HPA-1b/1b of integrin αIIbβ3 or α2 807TT of integrin α2β1, onto immobilized fibrinogen (left frame) or type I collagen (right frame), respectively. The 3 bottom panels show adhesion of platelets with the uncritical ‘wild-type’ receptor form, i.e. HPA-1a/1a or α2 807CC, under identical experimental conditions. The 2 middle panels represent control experiments with HPA-1b/1b platelets. Addition of abciximab, an αIIbβ3 blocking mAb, at a final concentration of 4 µg/ml caused >99% inhibition of platelet adhesion onto fibrinogen. No platelet adhesion was detected when coverslips had been coated with BSA. Note the presence of platelet aggregates (thrombi) on the collagen surface. These images are representative of the results obtained in 60 experiments with blood from healthy donors.

Fig. 7. Synergy of integrins α2β1 and αIIbβ3 to promote stable adhesion, aggregation formation and thrombus growth. Platelets in whole blood anticoagulated with trisodium citrate were incubated with mepacrine and allowed to adhere onto type I collagen at wall shear rates of 50 s⁻¹, 500 s⁻¹ or 1,500 s⁻¹ for 5 min in the absence (gray columns) or presence (black columns) of abciximab at a final concentration of 4 µg/ml. Absolute fluorescence intensity corresponding to the number of platelets attached per defined area and expressed as arbitrary (pixel) units was recorded at 1 and 5 min. Fluorescence intensity recorded at 1 min corresponds to platelet adhesion onto type I collagen, while data obtained at 5 min are representative of platelet aggregate or thrombus formation mediated by αIIbβ3 in the absence of abciximab. The amount of platelets attached is expressed as relative fluorescence defined as ratio of absolute fluorescence at 5 and 1 min. Bars represent mean ± SD of 5 five experiments with blood from different donors.

Software packages were available (MetaMorph, Molecular Devices, Sunnyvale, CA, USA; Image J, National Institute of Health, Bethesda, MD, USA). Using these experimental procedures and techniques, a striking difference in platelet adhesion rates onto fibrinogen or type I collagen was documented between homozygous HPA-1b and HPA-1a genotypes of αIIbβ3 or α2 807TT and α2 807CC of α2β1 at wall shear rates within the range of arteriolar flow (fig. 6). This finding is entirely in agreement with the previously proposed hypothesis derived from clinical association studies demonstrating prothrombotic effects of both integrin receptor variants, HPA-1b and α2 807TT. At shear rates relevant for hemostasis in arterioles as well as thrombosis in atherosclerotic arteries, αIIbβ3 and α2β1 are prominent players in mediating stable platelet adhesion and aggregation [37]. The role of αIIbβ3 as a key receptor for adhesive protein, notably fibrinogen and von Willebrand factor, that are involved in linking platelets to one another is well established [38]. As shown previously by Savage et al. [37], integrin α2β1 acts in concert with both the glycoprotein Ib-IX-V complex and its binding to immobilized von Willebrand factor as well as αIIbβ3 to promote stable adhesion and activation of platelets. This synergistic effect of the 3 key receptors with regard to thrombogenesis under arterial flow conditions was...
confirmed by our experiments (fig. 6). More importantly, adhesion and aggregate formation of platelets with combined critical genotypes of αIIbβ3 and α2β1, i.e. HPA-1b/1b and α2 807TT, were significantly increased compared to platelets with HPA-1a/1a and α2 807CC (p = 0.02). Thus, it is likely that the synergistic action of both integrins provides a reinforcement which is leading to increased thrombogenesis of their receptor variants but is inhibited in the presence of αIIbβ3 blocking mAbs (fig. 7).

In another series of experiments, the dynamics of thrombus formation was evaluated. For 3-dimensional analysis of thrombus growth over time (‘4-D’ imaging), a series of stacks, i.e. 30 confocal optical sections, from the bottom to the apex of the forming platelet thrombus, were obtained every 25 s with a 488-nm laser and a scanning time of <500 ms on an area of 26,450 µm². Images corresponding to an area of 0.202 µm² were analyzed by a ‘voxel’-based procedure, whereby a voxel is defined by a volume of 0.202 µm³ (0.45 µm² × 0.45 µm² × 1 µm). For calibration, fluorescent beads (Invitrogen, Carlsbad, CA, USA) were used, and the volume corresponding to a 1.0 µm thick stack was calculated pursuant to the voxel technique. With citrate-anticoagulated blood at an initial wall shear rate of 500 s⁻¹ and type I collagen under otherwise identical experimental conditions, as described above, thrombus volume reached a maximum after 420 s. Thrombus progression occurred in a 2-step way with an apical growth (height extension) at the interval of 220 and 300 s, and a further growth in the plane section at the interval of 300 to 420 s after perfusion [39]. Prolonged perfusion resulted in markedly abnormal flow patterns due to thrombus growth and increased shear rates (>500 s⁻¹). Interestingly, the HPA-1 polymorphism of αIIbβ3 had a dramatic effect on thrombus growth. Thus, when comparing blood from homozygous carriers of HPA-1b (n = 8) and HPA-1a (n = 8), thrombus formation and progression occurred more rapidly with HPA-1b than with HPA-1a platelets, resulting in significantly larger thrombi from HPA-1b than from HPA-1a individuals (p = 0.001) [39].

In summary, the voxel-based analysis of thrombus formation and progression under flow conditions can detect phenotypic differences related to the HPA-1 polymorphism of integrin αIIbβ3. Specifically, our results confirm in the experimental setting that HPA-1b is a thrombogenic receptor variant.

**Adhesion of Transfected Cells Expressing HPA-1b or HPA-1a of αIIbβ3**

A general problem of such studies in vitro, simulating physiological and pathological flow conditions, is the need for anticoagulation and, even more crucial, the notorious variability of platelet function assays. This is related, at least in part, to interindividual variability. To overcome these difficulties and to circumvent interindividual variability, we and others [40, 41] have generated transfected Chinese hamster ovary (CHO) cells expressing either HPA-1a or HPA-1b of αIIbβ3. We have examined these transfectants in the flow system described above and performed displacement experiments. Briefly, CHO cells were allowed to adhere onto immobilized fibrinogen at low shear rates (50–100 s⁻¹) and were then stepwise exposed to continuously increasing wall shear rates (up to 500 s⁻¹). Under these experimental conditions, HPA-1b cells were significantly more resistant to shear stress than the HPA-1a isoform. This observation is in agreement with results of others. Thus, Vijayan et al. [40, 41] reported that significantly more HPA-1b-transfected CHO cells bound to immobilized fibrinogen in an αIIbβ3-dependent manner than did HPA-1a cells. Such differences are likely to reflect changes in the nature or the efficiency of outside-in signals that are generated when αIIbβ3 encounters a thrombogenic substrate. Indeed, very recent findings demonstrate that the HPA-1b genotype of αIIbβ3 enhances outside-in signaling in human platelets by activating the serine/threonine phosphorylation of extracellular signal-regulated kinase and myosin light-chain [42]. In summary, the HPA-1b isoform of integrin αIIbβ3 confers a prothrombotic phenotype in human platelets and transfected CHO cells.

**Genotype-to-Phenotype and Phenotype-to-Disease Correlation**

One of the attractive aspects of positive epidemiologic association studies between platelet receptor polymorphisms and CAD is the biologic plausibility that variations in a critical hematostatic molecule will modify its function and induce a prothrombotic state [43, 44]. Such a contention assumes that a genetically determined receptor variant is causative for the disease and not merely linked to the causative gene. Indeed, as discussed in detail above, the functional characterization of the integrin receptors αIIbβ3 and α2β1 now provide a plethora of experimental data documenting a prothrombotic pheno-
type of both variants, HPA-1b and α2 807TT. Moreover, there are several indications that the Pro33 substitution in the β-subunit of αIbβ3 that results from a single nucleotide polymorphism (SNP) modulates ligand binding function and outside-in signaling of platelets and transfected cell lines. However, there is a number of limitations regarding a causative association of a polymorphism and its functional consequences. First, there is an apparent importance of lifelong risk interactions between environment and genetic polymorphisms [45]. While appreciable progress with regard to venous thromboembolic disorders has been made in terms of functional and clinical consequences of certain polymorphisms (e.g. G1691A mutation in the factor V gene), the development of arterial disease and its thrombotic complications (atherothrombosis) is less well understood. This is attributed to the complexity of the processes involved in vascular disease, in particular, the lack of knowledge about the interactions between environment and genetic polymorphisms [45]. Second, some of the problems in identifying causal genetic markers of arterial disease are related to the difficulties associated with the precise definition of the clinical phenotype under study. For example, there is plurality in clinical endpoints (e.g. myocardial infarction, unstable angina, CAD, progression of arterial disease or stroke) and, as evident from some of the clinical studies, these endpoints have been selected in a post-data collection search for significance [45]. In this context, the autopsy study by Mikkelson et al. [46] is of particular relevance reporting that the prevalence of HPA-1b was higher in individuals with myocardial infarction caused by thrombosis than in those without thrombosis (p < 0.001 unadjusted, p < 0.005 adjusted). Interestingly, these autopsy findings are consistent with the model depicted in figure 3 and hypothesized in our initial publication on HPA-1b [24]. Third, the importance of heritability of risk factors has generally not been fully appreciated. Moreover, the apparent paradox of a firm relationship between gene and protein and, even more striking, between protein and disease, but inconsistent gene-to-disease relationships, must be related to the quantitative contribution of heritability to the laboratory phenotype, e.g. the density of receptor expression on the platelet surface (fig. 8) [45]. However, the relationship between platelet receptor genotype and disease is currently unknown. Thus, the study of population genetics of polygenic disorders, such as arterial thrombotic disease, would require prior knowledge of i) the relationship between receptor density and disease, ii) the degree of heritability of variance in receptor density and iii) the genetic determinants of heritability [45]. Fourth, it is highly unlikely that single genetic polymorphisms can be the sole determinants of arterial disease. In this context, the distinction between risk factors leading to atherosclerosis and those causing increased platelet thrombogenicity, as proposed by our own findings [24, 25, 27], is an appealing hypothesis which, however, requires future detailed examination. Thus, further studies should be designed specifically to investigate the interactions between genetic polymorphisms of platelet receptors or other hemostatic components and acquired risk factors. It is conceivable that hemostatic genes have to interplay with other genetic or environmental effects before they can influence disease progression.

In conclusion, despite the significant progress that has been made within the last decade, we are far away from having established the genetic basis for arterial vascular disorders. There is a clear need for well-designed, large, prospective genetic epidemiological studies. In parallel to such clinical investigations, further in vitro studies of functional consequences of inherited traits are required to provide a sound rationale for risk-adapted prophylaxis and selective pharmacological strategies that will be beneficial to patients.

Acknowledgements

This work was supported by grants of the Deutsche Forschungsgemeinschaft (Sch 3583/1–1 and Sonderforschungsbereich 612 ‘Molecular analysis of cardiovascular functions and dysfunctions’, TPB2 ‘Modulation of platelet thrombogenicity through genetically determined variants of platelet integrins’). Additional support was provided by the Biological Medical Research Center, Heinrich Heine University, Düsseldorf, Germany. We thank Prof. Zaverio M. Ruggeri, The Scripps Research Institute, La Jolla, CA, USA, for providing mAbs (LJ-P4, LJ-CP8, LJ-Ibα) and purified human fibrinogen, Prof. Sanford J. Shattil and Prof. Mark H. Ginsberg, Department of Medicine, University of California San Diego, La Jolla, CA, USA, for PAC1 and anti-LIBS1, Prof. Volker Aurich and Dr. Andreas Beck, Institute of Informatics, Heinrich Heine University Düsseldorf, for their help with computation and image analysis. We express particular gratitude to Dr. Volkert Stoitd, Dr. Robert Loncar and Jan Peveling, M.D. student, for their invaluable experimental work including thrombus volume analysis. The technical assistance of Elisabeth Kirchhoff, Beate Maruhn-Debowski, Utv Vanderwappelle and Bianca Weingart is also acknowledged.

References


Hyperactive Platelets and Myocardial Infarction


